Global Community

About Roche Holding AG Roche is one of the world’s largest pharmaceutical companies, with a market capitalization of approximately CHF 300 billion (USD 380bn). The company operates through two primary divisions: •Roche Pharmaceuticals: A global leader in biotechnology and the leading provider of treatments for cancer.Read more

PRESCO operates in Oil Palm sector which has high entry cost and long gestation period. PRESCO has high margins (Gross & Net) and pricing power with specialized products including RBDO.Read more

Company Overview Founded in 2003 by Peter Thiel, Alex Karp, Stephen Cohen, Joe Lonsdale, and Nathan Gettings, Palantir Technologies emerged from the shared vision of transforming how data could be used to solve complex problems. Peter Thiel, a co-founder of PayPal and a prominent venture capitalist, brought his knack for identifying transformative opportunities.Read more

Corporate Profile and Operational Implications of Koç Holding Synergy Founded in 1963 with the aim of producing Türkiye's first intercity buses, Otokar has today transformed into a technology and industrial enterprise that develops, designs, and exports products with entirely its own intellectual property rights to more than 75 countries on 5 continents. The company's modern 555,000 m² production facility in Sakarya offers a high-capacity and flexible production infrastructure for both commercial vehicles and armored platforms for the defense industry.Read more

☁️ Business Overview Total: 12/17 +2 ✅✅ Projected Operating Margin: 50.69% +1 ✅ Projected 5-Year Revenue CAGR: 14.64% +2 ✅✅ Last 5-Year ROIC: 28.78% +1 ✅ Estimated Cost of Capital: 10.35% (lower than ROIC) +1 ✅ Last 5-Year Shares Outstanding CAGR: -0.50% +1 ✅ Projected 5-Year EPS CAGR: 18.36% +0 ⚠️ Projected 5-Year Dividend CAGR: 6.32% +2 ✅✅ Estimated Debt Rating: Aaa +2 ✅✅ Morningstar Moat: Wide +0 ⚠️ Morningstar Uncertainty: Medium Microsoft show its competitive advantages and pricing power through its stellar margins and higher revenue and EPS growth. This is reflected in its Morningstar Wide Moat rating.Read more

Merck’s 2026 narrative is a high-stakes drama centered on Keytruda , the world’s top-selling cancer drug. For years, the market has treated Merck like a "one-trick pony" due to the looming 2028 "patent cliff," where Keytruda will lose its legal protection and face generic competition.Read more

Recommendation: I remain sidelined, NEUTRAL (HOLD );— Slight bearish tilt Rating agencies' views reinforce a mixed picture: post-acquisition upgrades (Fitch to 'B+' IDR with 'BB' notes, Moody's to B2 stable, Morningstar DBRS to B(high) positive trend, S&P to 'B-' stable) reflect improved scale, synergy potential, and deleveraging path, with projected adjusted EBITDA margins largely resilient at 37-38% (S&P over 2025-2027), ~38% (Morningstar DBRS), and above 35% (Fitch pre-revision emphasis on margin expansion via integration). However, Fitch revised its outlook to Negative in December 2025 due to "material exposure to increased UK taxation," which will result in lower-than-previously-expected EBITDA (though not quantified as a sharp margin drop—management mitigated the 2026 impact to ~4% via €84M offsets, revising FY2026 EBITDA guidance to €420-440M from prior higher targets).Read more

In a nutshell: Hims & Hers’ recent investments are overlooked by investors, but they signal strongly revenue growth is not slowing down. The Starting Point Some analysts have low estimates for future revenue growth (approx.Read more

DMCI Holdings, Inc. is a diversified engineering conglomerate in the Philippines, engaged in construction, real estate, energy, mining, and water services.Read more